Literature DB >> 26569600

Impact of Poverty and Health Care Insurance on Arteriovenous Fistula Use among Incident Hemodialysis Patients.

Robert Nee1, Deepti S Moon, Rahul M Jindal, Frank P Hurst, Christina M Yuan, Lawrence Y Agodoa, Kevin C Abbott.   

Abstract

BACKGROUND: The impact of socioeconomic factors on arteriovenous fistula (AVF) creation in hemodialysis (HD) patients is not well understood. We assessed the association of area and individual-level indicators of poverty and health care insurance on AVF use among incident end-stage renal disease (ESRD) patients initiated on HD.
METHODS: In this retrospective cohort study using the United States Renal Data System database, we identified 669,206 patients initiated on maintenance HD from January 1, 2007 through December 31, 2012. We assessed the Medicare-Medicaid dual-eligibility status as an indicator of individual-level poverty and ZIP code-level median household income (MHI) data obtained from the 2010 United States Census. We conducted logistic regression of AVF use at start of dialysis as the outcome variable.
RESULTS: The proportions of dual-eligible and non-dual-eligible patients who initiated HD with an AVF were 12.53 and 16.17%, respectively (p<0.001). Dual eligibility was associated with significantly lower likelihood of AVF use upon initiation of HD (adjusted odds ratio (aOR) 0.91; 95% CI 0.90-0.93). Patients in the lowest area-level MHI quintile had an aOR of 0.97 (95% CI 0.95-0.99) compared to those in higher quintile levels. However, dual eligibility and area-level MHI were not significant in patients with Veterans Affairs (VA) coverage.
CONCLUSIONS: Individual- and area-level measures of poverty were independently associated with a lower likelihood of AVF use at the start of HD, the only exception being patients with VA health care benefits. Efforts to improve incident AVF use may require focusing on pre-ESRD care to be successful.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26569600     DOI: 10.1159/000441804

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  7 in total

Review 1.  Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society.

Authors:  Keith C Norris; Sandra F Williams; Connie M Rhee; Susanne B Nicholas; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; L Ebony Boulware
Journal:  Semin Dial       Date:  2017-03-09       Impact factor: 3.455

2.  Relative Effects of the Hospital Readmissions Reduction Program on Hospitals That Serve Poorer Patients.

Authors:  Jason H Wasfy; Vijeta Bhambhani; Emma W Healy; Christine Choirat; Francesca Dominici; Rishi K Wadhera; Changyu Shen; Yun Wang; Robert W Yeh
Journal:  Med Care       Date:  2019-12       Impact factor: 2.983

3.  Interdisciplinary Care and Preparedness for Kidney Failure Management in a High-Risk Population.

Authors:  Tanya S Johns; Kalyan Prudhvi; Rachel A Motechin; Kaltrina Sedaliu; Michelle M Estrella; Allison Stark; Carolyn Bauer; Ladan Golestaneh; L Ebony Boulware; Michal L Melamed
Journal:  Kidney Med       Date:  2022-03-17

4.  Racial Disparities in Arteriovenous Fistula Use Among Hemodialysis Patients: The Role of Surgeon Supply.

Authors:  Yi Zhang; Mae Thamer; Timmy Lee; Deidra C Crews; Michael Allon
Journal:  Kidney Int Rep       Date:  2022-04-12

Review 5.  Challenges and novel therapies for vascular access in haemodialysis.

Authors:  Jeffrey H Lawson; Laura E Niklason; Prabir Roy-Chaudhury
Journal:  Nat Rev Nephrol       Date:  2020-08-24       Impact factor: 28.314

6.  Area-level poverty, race/ethnicity & dialysis star ratings.

Authors:  Abhijit V Kshirsagar; Raj N Manickam; Yi Mu; Jennifer E Flythe; Andrew I Chin; Heejung Bang
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

7.  A mixed-methods investigation of incident Hemodialysis access in a safety-net population.

Authors:  Nicole C Rich; Shant M Vartanian; Shimi Sharief; Daniel J Freitas; Delphine S Tuot
Journal:  BMC Nephrol       Date:  2017-09-02       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.